An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of Nemtabrutinib in Participants With Severe Renal Impairment

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: All participants: * Has a body mass index (BMI) ≥18.0 and ≤40.0 kg/m\^2 Participants with Severe Renal impairment (RI): * The participant has stable renal function as determined by historical measurements. Healthy volunteers: * Is medically healthy with no clinically significant medical history Exclusion Criteria: The main exclusion criteria include but are not limited to the following: Renal Impairment Participants: * History of any illness, other than renal impairment, that, in the opinio…